Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMO phase 3 study of EYP-1901 versus aflibercept in diabetic macular edema
2025-523937-25-00Phase 3Authorised
- Sponsor
- EyePoint Pharmaceuticals
- Start
- May 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in diabetic macular edema (DME) comparing EYP-1901 with Aflibercept comparator (2 arms). Primary endpoint: Vision benefit over 56 weeks. Planned start May 2026; status: authorised.
02
Drugs
vorolanibaflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2025-523937-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523937-25-00.